Objective. We verified the usefulness of a new next-generation sequencing modality with the Lung Cancer Compact PanelTM using cytological specimens. Study Design. From December 2021 to February 2022, the wash fluid of lung tumors from 10 patients obtained using endobronchial ultrasonography (EBUS) with a guide sheath (GS), EBUS transbronchial needle aspiration (EBUS-TBNA), and pleural effusion puncture was examined with the Lung Cancer Compact PanelTM. We examined the patients medical records to obtain information on the analysis success rate and detection rate of gene mutations in consecutive cases searched for driver gene mutations. Results. Ten patients (6 lung adenocarcinoma, and 1 each of lung squamous cell carcinoma, small-cell lung cancer, renal cell carcinoma, and organizing pneumonia) and 12 samples (7 from brushing, 2 from EBUS-TBNA, 1 from a transbronchial biopsy [TBB] plus brushing, 1 from a TBB, and 1 from brushing) were examined using the Lung Cancer Compact PanelTM. We successfully analyzed all tests in all 10 patients (100%). EGFR L858R, KRAS G12D, or KRAS G12V was detected in lung adenocarcinoma patients. KRAS G12V was detected in the lung squamous cell carcinoma patient. The amounts of nucleic acids from the pleural effusion puncture and EBUS-TBNA were sufficient for the analyses. Conclusion. The Lung Cancer Compact PanelTM was useful for detecting gene mutations using cytological specimens.
|Translated title of the contribution||Usefulness of the High-sensitivity Lung Cancer Compact Panel TM with Cytological Specimens|
|Number of pages||7|
|Journal||Japanese Journal of Lung Cancer|
|Publication status||Published - Dec 20 2022|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine